Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for
Neurodegeneration and Lysosomal Storage Diseases
January 9, 2023
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’ disease
More here :